Get started
Author

Arturo Candal Gómez

Observed name: Arturo Candal Gomez
Observed institution: Centro Oncológico de Galicia
ORCID: 0009-0001-5997-0541
Observed ORCID: 0009-0001-5997-0541
OpenAlex ID: A5060749608
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
2021 · Xavier Garcia del Muro, Begoña P. Valderrama, et al. · Journal of Clinical Oncology · 35
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al. · Clinical Cancer Research · 21
Supplementary Table S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Table S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Table S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S5 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Data from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Table S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Table S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Table S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Table S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Table S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S3 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S5 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
Supplementary Figure S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al.
The role of PCA3 testing in a homogenenous population of patients with low and intermediate-risk prostate cancer treated with brachytherapy.
2014 · Ana Medina, Raquel Losada, et al. · Journal of Clinical Oncology
Works count: 22
Citation count: 56
H-index: 2
I10-index: 2
Year
Topic
Type